Research Update CHF 02806-MOU MY4: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up

The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. The study has two objectives. The first is to determine the most reasonable duration of an SOS test result. In other words, how long can a low-risk SOS test result be trusted and how much time might elapse between a high-risk SOS test result and the development of hemangiosarcoma. The second aim is to continue periodic testing for dogs previously enrolled in the Shine On study whose test result would have placed them in a high-risk category for development of hemangiosarcoma, and to provide eBAT as a strategy for prevention in up to 12 of these dogs. Continue reading “Research Update CHF 02806-MOU MY4: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”

Research Update CHF 02534 MY5 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

We have completed enrollment for the trial. We are currently analyzing the pharmacokinetic data obtained from the blood samples of dogs enrolled in the study. The project goals have not been modified.

Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy. Specifically:

Objective 1: We will confirm the tolerability and estimate the clinical benefit of propranolol in combination with doxorubicin.

Objective 2: We will assess levels of propranolol in the bloodstream after long-term administration to dogs with hemangiosarcoma to determine if there is a correlation between drug levels in blood and overall survival. We will also determine if propranolol alters the blood levels (exposure) of doxorubicin in dogs receiving propranolol and compare these levels to those found in the published literature fordogs receiving doxorubicin. Collection of these data will allow us to better understand how these drugs may be working together. Continue reading “Research Update CHF 02534 MY5 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update CHF 02534 EY 4 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

We have screened 58 dogs for the study. None of the dogs were enrolled due to the detection of metastatic disease during the screening process. Two other dogs were not screened due to the prior use of Yunnan Baiyao beyond the 24-hour limit allowed, and another owner cancelled the morning of the screening for unknown reasons. We have enrolled 19 dogs to date, bringing enrollment to 95% of the dogs proposed for the study. Continue reading “Research Update CHF 02534 EY 4 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update CHF 02806-MOU EY3: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up

The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. Continue reading “Research Update CHF 02806-MOU EY3: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”

Research Update CHF 02783 FINAL: Transcriptional Profiling of Canine Soft Tissue Sarcoma

Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis which we have completed. During all three years of the grant, we had excellent recovery rates from formalin-fixed tissue and have begun to generate sequencing data that can be layered onto the histologic findings and patient demographics.

FINAL, Research Update Transcriptional Profiling of Canine Soft Tissue Sarcoma

Research Update CHF 02780 FINAL: Bladder Carcinogen Exposures in Pet Dogs

Bladder cancer case recruitment is complete, assisted by a collaboration with Antech, which attached our study flyer to all BRAF urine tests that were positive for canine bladder cancer. We are awaiting the last batch of analyses for urinary chemicals (acrolein and arsenic) in dogs and their owners, as well as measurements of arsenic in tap water and household dust, and acrolein in household air. We hypothesize that these chemical exposures will be higher in bladder case homes compared to control homes. Continue reading “Research Update CHF 02780 FINAL: Bladder Carcinogen Exposures in Pet Dogs”

Research Update CHF 02519 Final: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations

We gained substantial and seemingly important information relative to the aims of this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. Subsequently, the COVID epidemic and loss of research personal resulted in repeated interruptions in our research efforts. After completing all Year I study aims, we continued to work on improvements in immunohistochemistry and FISH localization of Bartonella organisms within various cell types. Continue reading “Research Update CHF 02519 Final: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations”

Research Update CHF 02758 FINAL: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms

Thank you for supporting our project titled “Optical coherence tomography for margin evaluation of skin and subcutaneous neoplasms”. This project is investigating an emerging diagnostic imaging tool, optical coherence tomography that uses light waves to generate real time high-resolution images of tissues for detection of residual cancer cells immediately following surgical removal. Our team involves collaboration between veterinary medicine and pathology at the Ohio State University. We have completed enrollment of the 80 cases. We completed the first phase of this project where we are looking at imaging skin tumors after surgical removal in dogs. Continue reading “Research Update CHF 02758 FINAL: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms”

Research Update CHF 02783 MY3: Transcriptional Profiling of Canine Soft Tissue Sarcoma

Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis. Continue reading “Research Update CHF 02783 MY3: Transcriptional Profiling of Canine Soft Tissue Sarcoma”